Administration of rituximab during the first trimester of pregnancy without consequences for the newborn

M Ojeda-Uribe; C Gilliot; G Jung; B Drenou; A Brunot

doi:10.1038/sj.jp.7211481

Administration of rituximab during the first trimester of pregnancy without consequences for the newborn

J Perinatol. 2006 Apr;26(4):252-5. doi: 10.1038/sj.jp.7211481.

Authors

M Ojeda-Uribe¹, C Gilliot, G Jung, B Drenou, A Brunot

Affiliation

¹ Département d'Hématologie, Hôpital Emile Muller, Mulhouse Cedex, France. ojedam@ch-mulhlouse.fr

PMID: 16570081
DOI: 10.1038/sj.jp.7211481

Abstract

Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.

Publication types

Case Reports

MeSH terms

Adrenal Cortex Hormones / administration & dosage
Adult
Anemia, Hemolytic, Autoimmune / drug therapy*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents / administration & dosage*
Antirheumatic Agents / adverse effects
Drug Therapy, Combination
Erythrocyte Transfusion
Female
Humans
Infant, Newborn
Pregnancy
Pregnancy Complications, Hematologic / drug therapy*
Pregnancy Outcome
Pregnancy Trimester, First*
Recurrence
Rituximab
Treatment Refusal

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Rituximab